Tag: janssen

FDA approves two paediatric venous thromboembolism indications for Janssen’s Xarelto

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the US Food and Drug Administration (FDA) has approved two paediatric indications for...
reduced hospital time and costs Xarelto

Janssen submits new drug application to US FDA for Xarelto (rivaroxaban)...

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced it has submitted a new drug application (NDA) to the US Food and Drug...
reduced hospital time and costs Xarelto

FDA mini-sentinel assessment confirms safety and effectiveness of Xarelto (rivaroxaban) amidst...

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced findings from the US Food and Drug Administration's (FDA) mini-sentinel assessment, confirming the positive...

FDA approves new 10mg dosing for rivaroxaban to reduce continued risk...

Janssen Pharmaceuticals has announced that the FDA has approved the 10mg once-daily dose of rivaroxaban (Xarelto) for reducing the continued risk for recurrent venous...

FDA grants priority review of Xarelto for a 10mg dose to...

The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include...